Can the utility of secondary cytoreduction for ovarian cancer be reliably established?
Linda Duska
Correspondence Gillette Center for Women's Cancer, Massachusetts General Hospital, YAW 9, 55 Fruit Street, Boston, MA 02114–2617, USA
Email lduska@partners.org
This article has no abstract so we have provided the first paragraph of the full text.
The utility of primary cytoreductive surgery in advanced ovarian cancer has been well established in the literature; however, all published data are based on retrospective reviews. There are currently no published prospective randomized data specifically addressing primary cytoreduction, and there is a reluctance to study primary surgery in a randomized way, at least in the US, because this would entail having a group not receiving such surgery. There is a bias in favor of offering cytoreductive surgery to all suitable patients. Nevertheless, a meta-analysis of the literature in the 'platinum era' of upfront cytoreduction supports primary cytoreductive surgery.1
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.